Since the introduction of postpartum administration of antiRh(D) human immunoglobulin to the Rh-negative unsensitized women who bear an Rh-positive infant, there has been a dramatic decrease in maternal isoimmunization and a decrease of Rh hemolytic disease of the newborn (1). However, as a result of the diminishing population of naturally sensitized serum donors and increasing demand for antenatal prophylaxis (2), new sources of human anti-Rh antibody are needed.
Since the introduction of postpartum administration of antiRh(D) human immunoglobulin to the Rh-negative unsensitized women who bear an Rh-positive infant, there has been a dramatic decrease in maternal isoimmunization and a decrease of Rh hemolytic disease of the newborn (1) . However, as a result of the diminishing population of naturally sensitized serum donors and increasing demand for antenatal prophylaxis (2) , new sources of human anti-Rh antibody are needed.
In the last few years, several methods have been developed to generate cell lines producing human monoclonal antibodies (mAbs). Somatic cell hybridization between specific B lymphocytes and mouse myeloma cells has been hampered by the difficulty of establishing stable cell lines in culture, mostly because of the selective loss of human chromosomes (3, 4) . Sensitized B lymphocytes can be immortalized in vitro into B lymphoblastoid cell lines with EpsteinBarr virus (EBV) (5) . However, such cultures usually secrete low levels of antibodies and have tended to cease production after a variable period (6) . Human-human hybridomas secreting mAbs of predefined antigenic specificity have been described by several groups, including our own, but the yield of viable hybrids was too low for practical application (7) (8) (9) (10) (11) (12) .
Recently, a series of human-mouse heteromyeloma cell lines has been constructed and tested in our laboratory (13) . One of these lines, SHM-D33, consistently generates a high yield of viable hybrids. In addition, the ouabain resistance of this line allows the selection of hybrids after fusion with lymphoblastoid cell lines that have been shown to give high yields in fusions with myeloma cell lines (5, 9) . In this study, an anti-Rh antibody-producing lymphoblastoid cell line has been fused with SHM-D33 to generate numerous antiRho(D) antibody-producing hybrids.
MATERIALS AND METHODS Donor. Buffy-coat cells were obtained from a woman who had been sensitized to Rho(D) antigen during previous pregnancies. Her blood type was A Rhesus negative (Rh genotype: cde/cde) and her child was Rh positive (Rh genotype: CDe/cde). Two weeks after delivery, during routine postpartum examination and blood testing, a portion (20 ml) of the diagnostic specimen was collected in heparinized tubes. At that time, her anti-Rh antibody titer was 1024 (14) .
Generation of Anti-Rh-Specific Lymphoblastoid Cell Lines. Peripheral blood mononuclear cells were obtained by FicollHypaque density-gradient centrifugation. T lymphocytes were depleted by mass rosetting with neuraminidase-treated sheep erythrocytes followed by a second Ficoll-Hypaque gradient to purify nonrosetted B lymphocytes. Purified B lymphocytes were transformed with the B95-8 strain of EBV as described (5) . Emergent lymphoblastoid cells at a concentration of 2 x 106 cells per ml were mixed with an equal volume of a 4% solution of papain-treated O' human erythrocytes. The mixture was centrifuged at 800 x g for 10 min and placed on ice for 1 hr. Then the cells were gently resuspended and applied to a Ficoll-Hypaque density gradient. The rosette-forming cells were recovered from the erythrocyte pellet after lysis of the erythrocytes with a solution containing 0.14 M NH4Cl/0.01 M Tris HCl, pH 7.4, for 10 min at 370C.
Fusion Procedure. Lymphoblastoid cells were fused with the SHM-D33 heteromyeloma cell line as described (13) . Selection for hybrid cells was effected in hypoxanthine/aminopterin/thymidine medium (15) with 0.5 ,uM ouabain. Hybrids producing Rh antigen-specific human Ig were cloned by two cycles of limiting dilution. For the generation of an antibody-rich ascites, hybridoma cells (5 x 106) were injected intraperitoneally into pristine-primed nude mice.
Screening for Rh-Reactive Human mAbs. Culture supemnatants from wells exhibiting hybrid growth were initially screened for their ability to agglutinate papain-treated O+ human erythrocytes and their reactivity in an anti-Rh(D) ELISA as described (16 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tion in saline and by the indirect antiglobulin (Coombs) test (17) . Each test was carried out in the presence and absence of dithiothreitol. The postpartum serum of the patient served as a positive control, and culture supernatant from the parental heteromyeloma cell line provided a negative control in all experiments.
Anti-Rho(D) Specificity Test. Supernatants giving a positive hemagglutination reaction with papain-treated O' human erythrocytes were subsequently tested in the same conditions with papain-treated 0-human erythrocytes. They were then tested against a panel of human erythrocytes of known blood group genotypes (Resolve Panel A, Ortho, High Wycombe) by the Coombs technique (17) .
Characterization of the Hybridomas and Their Ig Products. Ig production was quantitated by ELISA (18) using heavychain specific goat anti-human Ig (Tago, Burlingame, CA) as well as by hemagglutination, with serial dilutions of culture supernatant. IgG subclasses were delineated using mAbs provided by Daniella Zelaschi (Department of Genetics, Stanford University, Stanford, CA). The hybrid nature and monoclonality of the hybridomas was established by Southern blot hybridization (19) using plasmid probes of the joining segment of the human Ig heavy chain genes and human X light-chain constant region as described (20, 21) . Newly synthesized immunoglobulins were labeled with [14C]leucine and then sodium dodecyl sulfate/polyacrylamide gel electrophoresis was carried out according to Laemmli (22) .
Virus Studies. EBV nucleic acid hybridizations were carried out as described (22), using plasmids pDK14 (BamHI-V) and pDK225 (BamHI-K) (23) containing the IR1 large repeat and IR3 presumed Epstein-Barr nuclear antigen (EBNA) coding region of the B95-8 strain of EBV (24), respectively. Tests for EBNA were kindly performed by Werner Henle (Department of Virology, Children's Hospital, Philadelphia). Reverse transcriptase activity was assayed as described (25) . Generation and Selection of the Hybridomas. The fused cells were selected in HAT medium containing 0.5 ,uM ouabain. After 2 weeks, proliferating hybrids were observed in 80% of the wells. All of the wells exhibiting hybrid growth contained human Ig in the culture supernatants by ELISA (22% IgG and 78% both IgG and IgM). Supernatant culture fluids tested for hemagglutination with papain-treated O0 human erythrocytes were 100% positive. The level of Ig production ranged from 0.5 tkg/ml to 20 Mug/ml, with a mean production of 8 ,g/ml per 106 cells per 24 hr. Twelve hybrids producing mAbs of the IgG isotype that gave the strongest hemagglutination reaction were subcloned by limiting dilution. More than 400 anti-Rh mAb-producing clones were obtained (all IgG, X chain) and those with the highest level of Ig production were selected for establishment of permanent cell lines. The identification of human Ig heavy-and lightchain genes in the cell lines by Southern blot analysis confirmed their hybrid nature and monoclonality (data not shown).
RESULTS

Derivation of
The secreted mAbs, when tested in saline solution, did not show hemagglutination. However, as expected for an IgG, positive reactivity was observed by using indirect antiglobulin and enzyme techniques (both in the presence and in the absence of dithiothreitol). The IgG subclasses of the clones were determined by using murine monoclonal antibodies with specificity for human IgG subclasses, and all of the antiRh Ig-producing clones thus studied were found to secrete IgG3. Biosynthetic radiolabeling of the hybridomas with
[14C]leucine, followed by immunoprecipitation and polyacrylamide gel electrophoresis of the secreted Ig confirmed the production of human y and X chains (Fig. 1) .
Specificity of the Anti-Rho(D) mAbs. The specificity of these mAbs for the Rho(D) antigen has been extensively analyzed by ELISA and hemagglutination techniques. As shown in Table 1 , a panel of human erythrocytes of different blood groups in the ABO and Rh systems has been tested with the culture supernatants and has revealed the specificity of the mAbs for the Rhesus structure. The hybridoma supernatants were tested with human erythrocytes of different Rh genotypes and reacted only with erythrocytes that express the Rho(D) antigen ( The current source of anti-Rh immune antisera, mostly from women naturally sensitized during pregnancy, is diminishing as a result of successful postpartum treatment with Rh-immune globulin. As an alternative to such naturally sensitized donors, volunteer Rh-negative donors immunized with Rh-positive blood have been used as a source of Rhimmune globulin. In addition to the need for frequent phlebotomies from donors, a serious disadvantage of human donor serum is the possibility of contamination by hepatitis and One of the primary concerns about the therapeutic use of antibodies produced by cell lines containing EBV or retroviruses is the possibility of viral contamination. In the present study, the negative reverse transcriptase analyses argue against the production of a murine retrovirus by the hybrid cells, while the EBV studies have shown that the majority of the hybrids do not retain the EBV genome. Although we have not been able to correlate the maintenance of the EBV genome with the presence of any specific human chromosomes in the hybrids, it can clearly be segregated from the genes coding for the structure and production of human Ig. This fact lends a major advantage to our system in comparison to previous reports of anti-Rh EBV-induced lymphoblastoid cell lines (31) (32) (33) . Additional advantages can be found in the greatly augmented level of Ig production and the ability of the hybridomas to grow and produce an antibody-rich ascites in nude mice. Furthermore, in contrast to most lymphoblastoid cell lines, which are known to lose Ig production after several months, the Ig production of clones D4-B2 and ElO-Cl has been stable for >8 months in continuous culture.
Although an 8-month follow-up does not yet allow us to conclude that fusion increases the stability of Ig production, the fact that our hybrids are producing mAbs composed of IgG3 X chains suggests that their chances of long-term stability are high. Indeed, it has been shown that the human chromosomes 14 (heavy-chain locus) and 22 (X-chain locus) are preferentially retained in human-mouse hybrids, while chromosome 2 (K-chain locus) is preferentially lost (34, 35) . The molecular cloning of the Ig genes resident in our hybridomas offers the hope of providing a perpetual standardized source of Rh-immune globulin.
The procedure we describe for the production of human mAbs recognizing the Rho(D) antigen holds both analytical and therapeutic promise. These reagents have proven useful in blood-group typing. They may also facilitate a more definitive biochemical characterization of the Rh antigen structure and help to explain the genetics of the Rh system. The techniques described here may also be applied to generate human mAbs against the Rh antigens implicated in a minority of cases of alloimmune hemolytic disease of the newborn (anti-c, anti-E, anti-Kell, and others) and could also prove useful in studies of the erythrocyte antigen systems involved in the pathogenesis of the autoimmune hemolytic anemias.
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